000 | 01983 a2200553 4500 | ||
---|---|---|---|
005 | 20250515163057.0 | ||
264 | 0 | _c20090604 | |
008 | 200906s 0 0 eng d | ||
022 | _a1473-5830 | ||
024 | 7 |
_a10.1097/MCA.0b013e3283229d97 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSteppich, Birgit Annette | |
245 | 0 | 0 |
_aIncreased circulating placental growth factor during percutaneous coronary intervention is associated with applied radiocontrast agent. _h[electronic resource] |
260 |
_bCoronary artery disease _cMar 2009 |
||
300 |
_a130-7 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAngina Pectoris _xblood |
650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
650 | 0 | 4 |
_aAnticoagulants _xtherapeutic use |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 | _aCase-Control Studies |
650 | 0 | 4 | _aCells, Cultured |
650 | 0 | 4 |
_aContrast Media _xadverse effects |
650 | 0 | 4 | _aCoronary Angiography |
650 | 0 | 4 |
_aCoronary Stenosis _xblood |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 |
_aEndothelial Cells _xdrug effects |
650 | 0 | 4 |
_aHeparin _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInterleukin-6 _xblood |
650 | 0 | 4 |
_aIopamidol _xadverse effects |
650 | 0 | 4 |
_aMyocardial Infarction _xblood |
650 | 0 | 4 | _aPlacenta Growth Factor |
650 | 0 | 4 |
_aPregnancy Proteins _xblood |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTriiodobenzoic Acids _xadverse effects |
650 | 0 | 4 | _aUp-Regulation |
650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xblood |
700 | 1 | _aKaufmann, Jan | |
700 | 1 | _aSepp, Dominik | |
700 | 1 | _aKunert, Katharina | |
700 | 1 | _aRutz, Tobias | |
700 | 1 | _aStratz, Christian | |
700 | 1 | _aOtt, Ilka | |
773 | 0 |
_tCoronary artery disease _gvol. 20 _gno. 2 _gp. 130-7 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1097/MCA.0b013e3283229d97 _zAvailable from publisher's website |
999 |
_c18732187 _d18732187 |